Skip to content
Precision for Medicine

Announcing the Institute@Precision, a Collaborative Forum for Biopharma Innovation.

patient-recruitement-2 patient-recruitement-mobile-2

Patient Recruitment Strategies

Finding the right patients for your trial can be challenging, especially when affected populations are small, such as for rare disease trials. Contact Us
Precision’s holistic patient recruitment approach leverages our global reach, extensive network of disease researchers, and patient advocacy groups to assemble a strategy to match the patient to your clinical trial based on your study’s criteria. For targeted therapeutics, we use biomarker-driven screening to find the patients expected to respond to your therapeutic, moving quickly and with confidence in data quality thanks to our in-house specialty lab services.

Smart patient recruitment strategies

Our network spans the globe, just like your patients do

patient_rec_img

Building relationships with communities and specialists

Patient advocacy group relationships and social media outreach help reach into affected communities.

Meanwhile, our established relationships with key opinion leaders and clinical research sites around the globe secure access to a wide range of patient populations.

Case Study: Enrolling a global natural history study: How to find 200 rare patients

A sponsor selected Precision to manage a global natural history study in a rare, X-linked kidney disorder. The study had been recommended by the FDA because there was extremely limited published data on this rare disease—the goal was to characterize renal function and decline in patients with the disease prior to initiating a phase 2/3 clinical study. The study, to be conducted in the United States, Canada, Australia and in Europe, would follow 200+ patients for approximately 2 years.

Enrollment was by far the greatest study challenge, combining a low disease prevalence and a primary target population—young males—with life commitments such as school and work that left little time for participation in a trial that offered no therapeutic benefit for participants and would require traveling to a clinic every 3 to 6 months.

Read the latest insights on Precision’s blog

Discover expert analysis and broaden your understanding through Precision’s Insights on current research, case studies, and trends. 

Read: Biomarker-Driven Clinical Trials in Oncology: Enrichment, Stratification, All-Comers & Basket Biomarker-Driven Clinical Trials in Oncology: Enrichment, Stratification, All-Comers & Basket

Biomarkers

Biomarker-Driven Clinical Trials in Oncology: Enrichment, Stratification, All-Comers & Basket

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=199138167916, hs_child_table_id=0, hs_updated_at=1762375981786, hs_published_at=1762376754681, avatar=Image{width=800,height=800,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Paul%20Steven.png',altText='Paul Steven',fileId=199144298570}, lastname=Steven, hs_initial_published_at=1762375986271, hs_created_by_user_id=26433386, hs_created_at=1762375951865, hs_is_edited=false, hs_deleted_at=0, name=Paul, job=Principal Biostatistician, slug=paul-steven, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Paul Steven avatar

    Paul Steven

Discover
Read: Investor Relations, Clinical Operations, and the Future of Biotech Financing Investor Relations, Clinical Operations, and the Future of Biotech Financing

Clinical Trials - Translational Research - Early Phase Research

Investor Relations, Clinical Operations, and the Future of Biotech Financing

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548862, hs_child_table_id=0, hs_updated_at=1716454315513, hs_published_at=1762376754681, description=Teresa is a respected business development strategist, building successful clinical programs for clients in Massachusetts. She is an innovator of fresh approaches to biomarker planning, translational solutions, and clinical study design. Her experience spans the execution of Phase 1-4 clinical trials, specialty lab services, companion and in vitro diagnostic strategies, and biomarker data management., avatar=Image{width=700,height=700,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Teresa-Pokladowski-300x300.png',altText='Teresa-Pokladowski-300x300',fileId=168135942975}, linkedin=https://www.linkedin.com/in/teresapokladowski/, lastname=Pokladowski, hs_initial_published_at=1713363230550, hs_created_by_user_id=5166971, hs_created_at=1713362443509, hs_is_edited=false, hs_deleted_at=0, name=Teresa, job=Regional Vice President, Clinical Business Solutions, North America, slug=teresa-pokladowski, hs_updated_by_user_id=26433386}, second={hs_id=197608580658, hs_child_table_id=0, hs_updated_at=1760465121471, hs_published_at=1762376754681, description=Hannah Dereseiwicz is a strategic force in investor relations, helping biotech innovators translate complex science into compelling narratives that drive engagement and growth. With a track record spanning commercial launches, M&A activity, and high-stakes communications, she brings clarity, confidence, and momentum to every stage of a company’s journey. Hannah’s approach is defined by the three A’s—ambitious, approachable, and authentic—making her a trusted partner for teams looking to elevate their story and connect with the audiences that matter most., avatar=Image{width=636,height=476,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Hannah%20Deresiewicz.webp',altText='Hannah Deresiewicz',fileId=197608718507}, lastname=Deresiewicz, hs_initial_published_at=1760465283803, hs_created_by_user_id=26433386, hs_created_at=1760464991513, hs_is_edited=false, hs_deleted_at=0, name=Hannah, job=Executive Vice President, Managing Director Precision AQ – Investor Relations & External Communications, slug=hannah-deresiewicz, hs_updated_by_user_id=26433386}, third={}})
  • Teresa P. avatar

    Teresa P.

  • Hannah D. avatar

    Hannah D.

Discover
Read: Clinical Trial Trends: Gene Therapy Clinical Trial Trends: Gene Therapy

Clinical Trials - Gene Therapies

Clinical Trial Trends: Gene Therapy

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548848, hs_child_table_id=0, hs_updated_at=1754641451547, hs_published_at=1762376754681, description=Alexis Hobbins-White is an accomplished leader who plays a pivotal role in navigating the complex landscape of global oncology and rare disease-focused clinical trials. With a career spanning over 15 years in the clinical trials industry, Alexis brings a wealth of experience across multiple therapeutic areas, showcasing her proficiency in diverse aspects of operational strategy. She specializes in early phase adaptive studies, particularly in immuno-oncology and advanced therapeutics. She has an MSc in Neuroscience and an MA in Biotechnology Law and Ethics., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Alexis-Hobbins.png',altText='Alexis-Hobbins',fileId=194096322982}, linkedin=https://www.linkedin.com/in/alexis-hobbins-white-400a1720/, lastname=Hobbins-White, hs_initial_published_at=1713362276020, hs_created_by_user_id=5166971, hs_created_at=1713361952861, hs_is_edited=false, hs_deleted_at=0, name=Alexis, job=Senior Director, Operational Strategy , slug=alexis-hobbins-white, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Alexis Hobbins-White avatar

    Alexis Hobbins-White

Discover